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Chung-Tsen Hsueh1, Delong Liu2* and Hong Wang3*A biomarker, as defined by Wikipedia, “is an indicator
of a biological state. It is a characteristic that is object-
ively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmaco-
logic responses to a therapeutic intervention.”Biomarkers for diagnosis and prognosis
Biomarkers have been used for clinical diagnosis of mul-
tiple diseases for many years, for example, troponin level
for diagnosing myocardial infarction, creatinine for diag-
nosing renal insufficiency, and amylase for pancreatitis.
Due to the objective values and convenience of measure-
ment with automated technology in the modern era, the
applications of biomarkers in biomedicine are increas-
ingly broader and vastly important. Immunophenotyping
by flowcytometry study of cell surface markers has
become an indispensable tool that hematooncologists and
hematopathologists rely on for diagnosing hematological
malignancies and monitoring minimal residual diseases.
Immunohistostaining of molecular markers have been
widely used for identifying cancer types. FLT3 and nucleo-
phosmin (NPM1) mutations are playing important
roles in individualizing treatment decisions on acute
myeloid leukemia. The applications of gene chips and
microarray technology to simultaneously assess mul-
tiple molecular markers are catching up to replace
single biomarker testing in guiding clinical practice
and are being commercialized faster than ever. As an
example, Oncotype Dx breast cancer test, a 21-gene
panel assay, provides personalized prediction of breast
cancer relapse risk and can potentially reduce un-
necessary adjuvant chemotherapy.* Correspondence: delong_liu@nymc.edu; hongw@temple.edu
2New York Medical College and Westchester Medical Center, Valhalla, NY
10595, USA
3Department of Pharmacology, Temple University School of Medicine, 3420
North Broad Street, Philadelphia PA 19140, U.S.A
Full list of author information is available at the end of the article
© 2013 Hsueh et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orBiomarkers for targeted therapy
Targeted agents are revolutionizing the cancer therapy.
From monoclonal antibodies (MoAb) to small molecule
inhibitors (SMIs) and immunoconjugates, more and
more targeted agents are quickly migrating from bench
to bedside. Rituximab, a MoAb against CD20, has essen-
tially changed the natural history of diffuse large B cell
lymphoma, and is effective in other B-cell disorders such
as rheumatoid arthritis. Trastuzumab, a MoAb blocking
Her2/neu, is an indispensible agent for Her2/neu posi-
tive breast cancer and metastatic gastric cancer. Bevaci-
zumab, a MoAb binding vascular endothelial growth
factor (VEGF), has been approved for the treatment of a
broad spectrum of advanced malignancies such as colo-
rectal, brain, kidney and non-small cell lung cancer
(NSCLC). Brentuximab vedotin (SGN-35), an immuno-
toxin conjugate, is now available for CD30 positive ana-
plastic large cell lymphoma and Hodgkin lymphoma.
BCR-ABL genetic rearrangement has served as a diag-
nostic biomarker for chronic myelogenous leukemia
(CML). Imatinib, a SMI of ABL, has led the way toward
modern-era therapy for CML, essentially changing allo-
geneic stem cell transplantation to the backseat. The dis-
covery of CD 117 expression on gastrointestinal stromal
tumor (GIST) escalated SMI therapy to another level,
turning the once most chemo-resistant malignancy to a
stunning success of targeted therapy [1,2]. Chemo-
resistant renal cell carcinoma (RCC) became sensitive to
SMIs, such as sorafenib, sunitinib, and pazopanib. Evero-
limus and temsirolimus, the class of mTOR inhibitors,
have also shown significant activity toward RCC and
other malignancies. SMI and MoAb of epidermal growth
factor receptor (EGFR) such as gefitinib, erlotinib, cetu-
ximab, panitumumab, are widely used for the treatment
of lung, colon, and pancreatic cancers. Crizotinib, an
anaplastic lymphoma kinase (ALK) inhibitor, is another
biomarker targeting agent against NSCLC harboring
ALK translocation, which is mutually exclusive from
EGFR mutation.Ltd. This is an Open Access article distributed under the terms of the Creative
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late clinical development for advanced melanoma, one of
the most chemo-refractory cancers [3]. Vemurafenib, an
inhibitor of BRAF V600E mutant, has been approved for
advanced melanoma therapy. Ipilimumab, a MoAb against
CTLA-4, has demonstrated efficacy in patients with
advanced melanoma. Trametinib, a SMI against MEK, has
shown promising activity against BRAF mutated mela-
noma and may provide an alternative for patients who are
resistant to BRAF targeting therapy in the future.
JAK2 V617F mutation is the most important biomarker
in myeloproliferative neoplasms (MPN). Ruxolitinib, a
JAK inhibitor, has been shown to decrease splenomegaly
and alleviate symptoms associated with MPN associated
with advanced myelofibrosis. More JAK2 –specific inhibi-
tors are undergoing clinical trials.
With the vast knowledge of signal transduction pathways,
SMIs are being developed for many known biomarkers,
such as PI3K, Bruton’s tyrosine kinase, c-MET, RET, etc.
Biomarkers as surrogate endpoint for clinical trials
It often takes years to reach the traditional endpoints in
clinical trials, such as overall survival, progression free
survival, etc. in non-selected patient populations. This is
costly and time-consuming. Biomarkers are getting re-
cognition to serve as surrogate endpoints in cancer trials
and help to timely identify patients who will benefit
from the specific targeted therapy agents. As an ex-
ample, BCR-ABL transcript level was recognized as a
surrogate biomarker endpoint (major molecular re-
sponse at 12 months) in ENESTnd trial [4], since it was
shown to have correlation with 5-year survival in IRIS
trial. It is foreseeable that more biomarkers will replace
those time-consuming traditional endpoints, accelerating
the translation of novel agents from bench to bedside.
Another example is the unprecedented speedy develop-
ment of vemurafenib for patients with BRAF V600E mu-
tation. It took less than six years from drug discovery to
health authority approval for clinical use. Patients with
BRAF V600E showed early and dramatic responses to
vemurafenib even in a phase I study. Subsequently all
phase II and III studies were conducted in selected me-
lanoma patients with BRAF V600E mutation, which
confirmed the phase I study findings and demonstrated
improved response rate and overall survival in vemurafe-
nib treated patients [5]. Clearly more specific biomarkers
will be implemented in the future clinical studies and
will help to tailor patient’s best care in a new era of per-
sonalized medicine.
To facilitate the growth of this rapidly developing
multidisciplinary field, Biomarker Research aims to pub-
lish original discovery, novel concepts, commentaries,
new methodologies, and reviews related to biomarker
investigation from all biomedical disciplines.Acknowledgement
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